P45 Are There Any Differences in the Recommendations for Ultra Orphan Medications: An Assessment of NICE, GBA, and HAS

Ultra orphan drugs pose challenges in the health technology assessment (HTA), reimbursement, and pricing due to limited patient population and data, resulting in high decision uncertainty. Considering these challenges, we aim to examine the outcomes for ultra orphan drugs appraised by NICE, GBA, and HAS.
Source: Value in Health - Category: International Medicine & Public Health Authors: Tags: Differences and New Developments in HTA Around the World Source Type: research